# HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

> **NIH NIH N01** · ALBANY MOLECULAR RESEARCH, INC. · 2024 · $456,391

## Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.

 Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia
Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract).
to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption,
distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided
Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor in developing a novel therapeutic effective in
treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of
starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.

## Key facts

- **NIH application ID:** 11041795
- **Project number:** 271201800001I-P00002-759502200007-1
- **Recipient organization:** ALBANY MOLECULAR RESEARCH, INC.
- **Principal Investigator:** MATT SURMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $456,391
- **Award type:** —
- **Project period:** 2022-09-28 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11041795

## Citation

> US National Institutes of Health, RePORTER application 11041795, HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I (271201800001I-P00002-759502200007-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11041795. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*